The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse
Open accessAbstract
Nonstandard abbreviations used: systemic lupus erythematosus (SLE); double-stranded DNA (dsDNA); glomerulonephritis (GN); recombinant IL-12 (rIL-12); recombinant IFN-γ (rIFN-γ); concanavalin A (ConA); histone deacetylase (HDAC); histone deacetylase inhibitor (HDI); trichostatin A (TSA); suberonylanilide hydroxamic acid (SAHA); body weight (BW); PBS containing 0.05% Tween (PBS-T); glomerular basement membrane (GBM).including anti-double-stranded DNA (anti-dsDNA) autoantibodies and hypocomplementemia by 12-16 weeks of age; and (c) clinical signs of arthritis, massive lymphadenopathy, splenomegaly, vasculitis, and glomerulonephritis (GN) by the age of 16-24 weeks.Fifty percent of MRL-lpr/lpr mice die by 24 weeks of age, primarily from renal failure (2).Although the etiology of SLE is unknown, a number of key mediators of disease have been identified.Cytokines produced by Th1 and Th2 lymphocytes play a major role in the immunopathogenesis of human and murine SLE (3).Studies of cytokine mRNA and protein in MRLlpr/lpr mice with established disease have documented that splenic Th1 and Th2 subsets are constitutively activated (4).These T cells produce heightened levels of specific cytokines that contribute directly to the aberrant immune response that ultimately leads to dysregulated autoantibody production (3, 4).IFN-γ is a Th1 cytokine that enhances production of IgG2a and IgG3; moreover, this cytokine accelerates GN in both NZB/W F 1 and MRL-lpr/lpr murine models of SLE.In vivo administration of IFN-γ accelerates the disease process, whereas treatment with monoclonal anti-IFN-γ antibody or soluble IFN-γ receptor significantly delays the disease in NZB/W F 1 mice and, to a lesser extent, in MRL-lpr/lpr mice (5, 6). IL-12 is also a Th1 cytokine that promotes differentiation of Th1 CD4 + cells. Administration of IL-12 accelerates GN by promoting intrarenal accumulation
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
REGULATION OF IMMUNE RESPONSES BY TGF-β
Letterio, J. J., & Roberts, A. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.137 · Cited by 1,890
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Murine Models of Systemic Lupus Erythematosus
Theofilopoulos, A. N., & Dixon, F. J. (1985) · Advances in Immunology · doi:10.1016/s0065-2776(08)60342-9 · Cited by 1,550
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
What's Up and Down with Histone Deacetylation and Transcription?
Pazin, M. J., & Kadonaga, J. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80211-1 · Cited by 821
Deacetylation of p53 modulates its effect on cell growth and apoptosis
Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. (2000) · Nature · doi:10.1038/35042612 · Cited by 818
Cited by
Tsokos, G. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100359 · Cited by 2,736
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
New insights into the immunopathogenesis of systemic lupus erythematosus
Tsokos, G. C., Lo, M. S., Reis, P. C., & Sullivan, K. E. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.186 · Cited by 1,226
Epigenetics in health and disease
Zhang, L., Lu, Q., & Chang, C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3449-2_1 · Cited by 689
Trained immunity — basic concepts and contributions to immunopathology
Ochando, J., Mulder, W. J. M., Madsen, J. C., Netea, M. G., & Duivenvoorden, R. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00633-5 · Cited by 453
Murine Models of Systemic Lupus Erythematosus
Perry, D., Sang, A., Yin, Y., Zheng, Y.-Y., & Morel, L. (2011) · BioMed Research International · doi:10.1155/2011/271694 · Cited by 378
Oxidative stress in the pathology and treatment of systemic lupus erythematosus
Perl, A. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.147 · Cited by 358
Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy
Avila, A. M., Burnett, B. G., Taye, A. A., Gabanella, F., Knight, M. A., Hartenstein, P., Cizman, Z., Di Prospero, N. A., Pellizzoni, L., Fischbeck, K. H., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29562 · Cited by 350
The type I interferon system in systemic lupus erythematosus
Rönnblom, L., Eloranta, M., & Alm, G. V. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21571 · Cited by 341
Leoni, F., Fossati, G., Lewis, E. C., Lee, J.-K., Porro, G., Pagani, P., Modena, D., Moras, M. L., Pozzi, P., Reznikov, L. L., et al. (2005) · Molecular Medicine · doi:10.2119/2006-00005.dinarello · Cited by 337
Hull, E. E., Montgomery, M. R., & Leyva, K. J. (2016) · BioMed Research International · doi:10.1155/2016/8797206 · Cited by 313
Histone Hyperacetylation Is Associated with Amelioration of Experimental Colitis in Mice
Glauben, R., Batra, A., Fedke, I., Zeitz, M., Lehr, H. A., Leoni, F., Mascagni, P., Fantuzzi, G., Dinarello, C. A., & Siegmund, B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.5015 · Cited by 293
Reddy, P., Maeda, Y., Hotary, K., Liu, C., Reznikov, L. L., Dinarello, C. A., & Ferrara, J. L. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400380101 · Cited by 266
Reddy, P., Sun, Y., Toubai, T., Duran-Struuck, R., Clouthier, S. G., Weisiger, E., Maeda, Y., Tawara, I., Krijanovski, O., Gatza, E., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34712 · Cited by 265
Epigenetic alterations in autoimmune rheumatic diseases
Ballestar, E. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.16 · Cited by 173
Sanderson, L., Taylor, G. W., Aboagye, E. O., Alao, J. P., Latigo, J. R., Coombes, R. C., & Vigushin, D. M. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000638 · Cited by 90
Metabolic control of the epigenome in systemic Lupus erythematosus
Oaks, Z., & Perl, A. (2014) · Autoimmunity · doi:10.3109/08916934.2013.834495 · Cited by 76
Nishioka, C., Ikezoe, T., Yang, J., Komatsu, N., Bandobashi, K., Taniguchi, A., Kuwayama, Y., Togitani, K., Koeffler, H. P., & Taguchi, H. (2008) · Leukemia Research · doi:10.1016/j.leukres.2007.05.026 · Cited by 58
Molecular events in kidney ageing
Famulski, K. S., & Halloran, P. F. (2005) · Current Opinion in Nephrology and Hypertension · doi:10.1097/01.mnh.0000165890.60254.4e · Cited by 53
Metadata
- Authors
- Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P., & Gilkeson, G. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-02-15
- Volume
- 111
- Issue
- 4
- Pages
- 539-552
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2108639843
- Cited by
- 408
- References
- 63
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.